

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**GENERTEC UNIVERSAL MEDICAL GROUP COMPANY  
LIMITED**

**通用環球醫療集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code : 2666)**

**ANNOUNCEMENT IN RELATION TO THE PROPOSED ISSUANCE OF  
THE FIRST TRANCHE OF DOMESTIC MEDIUM-TERM NOTES  
IN THE PRC  
BY CHINA UNIVERSAL LEASING CO., LTD., A WHOLLY-OWNED  
SUBSIDIARY OF THE COMPANY**

This announcement is made by Genertec Universal Medical Group Company Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (the “**Issuer**”), a wholly-owned subsidiary of the Company, had registered the issuance of the domestic medium-term notes with the National Association of Financial Market Institutional Investors (中國銀行間市場交易商協會) of an aggregate principal amount of up to RMB2 billion in the People’s Republic of China (the “**PRC**”). As of the date of this announcement, the balance of the principal amount was RMB0.5 billion.

The Issuer has decided to launch the issuance of the first tranche of the domestic medium-term notes for year 2025 to domestic institutional investors in the PRC with an aggregate principal amount of up to RMB0.5 billion (the “**T1 Notes**”). The T1 Notes are with a term of three years and a fixed interest rate which will be determined at the end of the subscription period through book-building processes. The net proceeds from issuance of the T1 Notes are intended to be used for repaying maturing debts of the Issuer.

The T1 Notes will be issued to domestic institutional investors in the PRC (other than those who are restricted from participating in such offering in accordance with the laws and regulations of the PRC). Postal Savings Bank of China Co., Ltd. (中國郵政儲蓄銀行股份有限公司), Industrial Bank Co., Ltd. (興業銀行股份有限公司), Bank of Beijing Co., Ltd. (北京銀行股份有限公司), Bank of Hangzhou Co., Ltd. (杭州銀行股份有限公司) and China Everbright Bank Co., Ltd (中國光大銀行股份有限公司) are the joint lead underwriters for the issuance of the T1 Notes.

Other principal terms of the T1 Notes to be issued are as follows:

Place of issuance:	the inter-bank bond market in the PRC
Par value:	RMB100.0
Issue price:	RMB100.0
Credit rating of the Issuer:	AAA rating for the Issuer
Trading arrangement:	The T1 Notes are expected to be traded on the inter-bank bond market in the PRC from 1 April 2025.

In accordance with the relevant laws and regulations in the PRC, relevant documents in relation to the Issuer and the T1 Notes will be published on the websites of Shanghai Clearing House (<http://www.shclearing.com>) and China Foreign Exchange Trade System ([www.chinamoney.com.cn](http://www.chinamoney.com.cn)), respectively. Shareholders of the Company and potential investors are reminded that such documents were prepared in accordance with the requirements in the PRC and are limited solely to the Issuer, and the information contained therein does not provide a full picture of the operation status of the Company and its subsidiaries.

Further announcement(s) will be made by the Company in relation to the updated progress of issuance of the T1 Notes as and when appropriate.

By order of the Board  
**Genertec Universal Medical Group Company  
Limited**  
通用環球醫療集團有限公司  
**Chen Shisu**  
*Chairman of the Board*

Beijing, PRC, 26 March 2025

*As at the date of this announcement, the executive directors of the Company are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive directors of the Company are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.*